BOZEN, Sud-Tirol, Italy--(BUSINESS WIRE)--Health Robotics announced its upcoming schedule for additional regional events, [http://www.health-robotics.com/en/about-health-robotics/events/] inviting interested pharmacy professionals to visit the company’s Second Generation solutions at symposia in Albany [NY] and Houston [TX], to network with their peers and Health Robotics’ distributor’s personnel at the New York Pharmacy Technology Summit [March 21], and the Texas Society of Health-System Pharmacists [April 11-12], including setting up site visits to hospital peers utilizing Health Robotics’ solutions.
Gaspar DeViedma, Health Robotics’ Executive Vice President, stated: “As we started supporting regional events in 2013 with the California Society of Health-System Pharmacists, we are continuing on this path in 2014, showcasing New York’s new installations at Albany Medical Center, Maimonides Medical Center, University of Rochester Medical Center, and Texas’ Michael DeBakey Veterans Administration Medical Center, where Health-System pharmacists can compare and contrast Health Robotics’ world leading solutions, without the hype routinely uttered by its global competitors1, whose bids were rejected by these institutions.”.
At the New York Pharmacy Technology Summit in Albany, Health Robotics’ customers’ William Churchill from Brigham and Women’s Hospital in Boston, and Dave Webster from University of Rochester Medical Center are scheduled to offer their expert opinions during keynote presentations and follow-up panel discussions.
Mr. DeViedma continued: “One competitor (Intelligent Hospital Systems-RIVA) routinely claims to be the only robot with “true walk-away capabilities”, which is utter nonsense considering that even old IV Robots have had this feature for decades. In my opinion, this hype only demonstrates that it takes RIVA’s users so long to load and so long to process IV doses that they truly have to “walk away” and come back several hours later or even the next day in order to retrieve the IV output. This IHS “unattended” claim is also counterintuitive to the same company’s claim that it takes 1.5 FTEs to support RIVA. What are the 1.5 RIVA FTEs necessary for, if this is true? Similarly, another competitor (APOTECAchemo) routine propaganda was widely exposed2 for its ongoing problems at the November 15th edition of the American Journal of Health System Pharmacy.”
Overwhelmingly, pharmacists continue to recognize the undeniable fact that Health Robotics’ Second Generation architecture of integrated and networked medical devices are fully-automated, with automatic labeling and tamper-resistant capping, offering 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than its major competitors1, while delivering payback periods/R.O.I. ranging from 6 months for i.v.STATION to 1.5 years for i.v.STATION ONCO.
About Health Robotics:
Founded
in 2006, Health Robotics is the undisputed leading supplier of
life-critical sterile compounding Robots with greater than 80% total IV
Robots market share in the world [including over 90% the Oncology Robots
global market]. Health Robotics provides near 600 hospital installations
in 5 continents with the only fully integrated, robotics-based
technology, IV Workflow, and manual compounding software automation
solutions. Health Robotics’ second-generation-platform products
[i.v.STATION®, i.v.SOFT®, i.v.STATION®
ONCO, and i.v.STATION® 2 for TPNs] have been proven [through
scientific and peer-reviewed studies3, 4, 5] to greatly
contribute to ease hospitals’ growing pressures to improve patient safety3,
increase throughput3, and contain costs3. Through
the effective and efficient production of sterile, accurate,
tamper-evident, and ready-to-administer IVs and TPNs, Health Robotics’
medical devices and integrated workflow solutions help hospitals
eliminate life-threatening drug3 and diluent exchange errors,
improve drug potency4, decrease other medical mistakes3
and sterility risks, work more efficiently3, reduce waste3
and controlled substances’ diversion, decrease pharmacy technician
upper-limb injuries5, and diminish the gap between rising
patient volume/acuity and scarce nursing and pharmacy staff3.
1 Competitors: Intelligent Hospital Systems/RIVA, Fresenius
Kabi/MDS, Baxter/Baxa, and Loccioni.
2 Implementation
of an i.v.-compounding robot in a hospital-based cancer center pharmacy;
Am J Health Syst Pharm November 15, 2013 70:2030-2037
3 Impact
of Robotic Antineoplastic Preparation on Safety, Workflow, Costs.
Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick,
Wien, Cotugno, Bates, and Rothschild. Brigham & Women’s Hospital,
Massachusetts College of Pharmacy, and Harvard Medical School. Journal
of Oncology Practice, Nov. 2012, Volume 8, number 6.
4 Validation
of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin®, Remicade®, and Herceptin®.
Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs
January 2013, Volume 5, Issue 1.
5 Comparing
the upper limb disorder risks associated with manual and automated
cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin,
Dean, Franklin. Imperial College Healthcare NHS Trust. European Journal
of Hospital Pharmacy April 2012.
